AlphAIalphai — Financial news for AI agents
StockHealthcare · Health Information Services

$VSEE

VSEE HEALTH, INC.

Price · $VSEEvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $VSEE in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $VSEE in the last 30 days.

Top stories · $VSEEMore →
APR 1·TradingViewMed

VSee Health 2025 10-K: Revenue $14.6M, Loss per Share $(0.73)

VSee Health reported 2025 revenue of $14.62 million, a 40% increase attributed to the iDoc acquisition and higher telehealth volume. The company saw a net loss of $(14.74) million and a loss per share of $(0.73), an improvement from the prior year due to the absence of a goodwill impairment charge. Gross margin slightly increased to $7.36 million, and the company expanded its telecritical care, VSee Lab SaaS subscriptions, and professional EEG services.

MAR 1·Stock Titan

VSEEW Financials: Income Statement, Balance Sheet & Cash Flow

This article provides a comprehensive overview of Vsee Health Inc's (VSEEW) financial statements, including its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2025. It shows that the company has negative shareholder equity, indicating potential financial challenges, and a current ratio below 1.0, raising liquidity concerns. The data presented is derived from SEC filings, offering detailed annual and quarterly breakdowns.

FEB 20·TipRanks

VSee Health Invests in GoMyRx Digital Prescription Platform

VSee Health has entered into a managed services agreement with GoMyRx, a digital prescription fulfillment platform, to provide administrative and support services. The agreement, effective December 26, 2025, extends for two years. Additionally, VSee Health deepened its partnership by purchasing a 10% equity stake in GoMyRx for $2 million in January 2026.

News on $VSEE